Investors - Press Releases
New Study Predicts Risks of Drug Interactions without Exposing Patients to Harm
The study, published online in Clinical and Translational Science, used TRHC's proprietary MedWise medications safety technology to virtually assess the potential risk of adverse drug events (ADEs) when adding repurposed drugs for COVID-19 treatment to the individual medications of a large-scale population. The results demonstrate that medication risk scores could be used to effectively assess drug safety before exposing patients to repurposed drugs.
"Through this innovative simulation we have demonstrated the value of our MedWise technology as part of a blueprint to assess the safety of newly prescribed repurposed drugs without exposing real patients to potential harm," said TRHC Chairman and CEO
The simulated risk assessment examined de-identified medical information from approximately 500,000 Medicare and commercially insured Regence Health Plan members. Researchers determined each person's baseline MedWise Risk Score™ (MRS) and simulated the addition of five drugs repurposed for COVID-19 treatment. The change in the MedWise Risk Score was used as a predictive tool to assess the risk of adverse drug events associated with repurposed drugs for COVID-19.
"Using a simulation-based approach, we are able to apply scientific data on the drugs' mechanisms and metabolisms to determine how these drugs would alter a patient's medication risk score—without putting the patients at risk," said
"We are very pleased to be a part of this novel simulation-based clinical study," said
Regence serves approximately 3.3 million people through its health plans in
View original content to download multimedia:http://www.prnewswire.com/news-releases/new-study-predicts-risks-of-drug-interactions-without-exposing-patients-to-harm-301287900.html
Anthony Mirenda, 908-380-2143, email@example.com